Andrada Larisa Deac, MD, Doctor, Department of Medical Oncology, "Prof.Dr.Ion Chiricuta" Oncology Institute from Cluj-Napoca, Republicii Street, Cluj-Napoca 400015, Cluj, Romania. andrada.deac@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Dec 24, 2020; 11(12): 1008-1017 Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.1008
Fluoropyrimidine-induced cardiotoxicity
Andrada Larisa Deac, Claudia Cristina Burz, Ioana Corina Bocsan, Anca Dana Buzoianu
Andrada Larisa Deac, Department of Medical Oncology, "Prof.Dr.Ion Chiricuta" Oncology Institute from Cluj-Napoca, Cluj-Napoca 400015, Cluj, Romania
Claudia Cristina Burz, Department of Immunology and Allergology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca 400015, Cluj, Romania
Ioana Corina Bocsan, Anca Dana Buzoianu, Department of Pharmacology, Toxicology and Clinical Pharmacology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca 400015, Cluj, Romania
Author contributions: Deac AL performed the majority of the writing, designed the tables and figures; Deac AL, Burz CC, Bocsan IC, Buzoianu AD designed the study; Deac AL performed the research on medical literature; all authors have read and approved the final manuscript.
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Andrada Larisa Deac, MD, Doctor, Department of Medical Oncology, "Prof.Dr.Ion Chiricuta" Oncology Institute from Cluj-Napoca, Republicii Street, Cluj-Napoca 400015, Cluj, Romania. andrada.deac@gmail.com
Received: June 8, 2020 Peer-review started: June 8, 2020 First decision: September 18, 2020 Revised: September 27, 2020 Accepted: October 20, 2020 Article in press: October 20, 2020 Published online: December 24, 2020 Processing time: 192 Days and 24 Hours
Abstract
Cardio-oncology is a discipline based on early screening, monitoring, and treating chemotherapy-induced cardiotoxicity. There are many chemotherapeutics known for their cardiac toxic effects, including fluoropyrimidines. Fluoropyrimidine represents the cornerstone of many types of cancer and each year almost two million cancer patients undergo this treatment. Fluoropyrimidine-induced cardiotoxicity can be manifested in several forms, from angina pectoris to sudden death. This paper is a review of how the cardiotoxicity of fluoropyrimidines is presented, the mechanisms of its occurrence, its diagnosis, and management.
Core Tip: There are several reviews and cases which showed fluoropyrimidine-induced cardiotoxicity. However, this mini-review includes useful information on clinical manifestations, pathophysiological mechanisms, diagnosis, and management of fluoropyrimidine-induced cardiotoxicity.
